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Objective: To present the case of a female collegiate
basketball player who was diagnosed with Wegener granulo-
matosis of the eyes and immunoglobulin A (IgA) nephropathy.
Background: A 19-year-old female collegiate basketball
player presented to a rheumatologist, urologist, and nephrolo-
gist with severe eye pain and was diagnosed with Wegener
granulomatosis and IgA nephropathy. At age 20, during routine
follow-up testing, urine protein levels were found to be 3 times
normal values (0–8 mg/dL), prompting the need for a kidney
biopsy, which showed IgA nephropathy, another autoimmune
disorder.
Differential Diagnosis: Sinus infection, scleritis, lymphoma-
toid granulomatosis, Churg-Strauss syndrome, lupus erythema-
tosus, general granulomatosis.
Treatment: Initial assessment revealed signs and symp-
toms, particularly in the patient’s eyes, consistent with a sinus
infection and scleritis. Her corneas were examined by a
specialist, who prescribed various medications, including
prednisone, for the relief of symptoms. When the dosage of
prednisone was reduced, symptoms returned. Further tests
revealed the presence of anti-neutrophil cytoplasmic antibody, a
protein associated with Wegener granulomatosis, which helped
confirm the diagnosis. The following year, a routine urinalysis
showed abnormal levels of protein in her urine. A kidney biopsy
revealed that IgA nephropathy also was present. At the time of
this case report, the athlete continues to be monitored by an
ophthalmologist who specializes in Wegener granulomatosis, a
rheumatologist, and a nephrologist.
Uniqueness: This athlete presented with 2 rare autoimmune
disorders at an early stage of life. The medications used to treat
the disorders left the athlete fatigued on a daily basis.
Additionally, she was placed on 3 immunosuppressant drugs,
which increased her risk for further health complications, yet she
was able to successfully compete in athletics at the collegiate
level. No family history of renal disease or other autoimmune
disorders was discovered, further adding to the complexity and
uniqueness of this case.
Conclusions: Autoimmune disorders, such as Wegener
granulomatosis, can present with a variety of common signs
and symptoms. As athletic trainers, we encounter a host of
unusual signs and symptoms; however, in cases such as this,
further investigation into the cause of the chief complaints can
go a long way toward restoring or managing an athlete’s health.
Excellent communication among the sports medicine team
helped this athlete manage her potentially life-threatening
condition while allowing her to remain active in her sport.
Key Words: Wegener granulomatosis, nephropathy, predni-
sone, immunosuppressants, autoimmune disorders
C
omplications from autoimmune disorders can
greatly affect a patient’s daily activity, including
sport participation, and may require treatment with
various medications that place additional strain on the
body and leave the patient susceptible to other illnesses.1
Autoimmune disorders can present during many stages of
life. Some autoimmune disorders, such as diabetes mellitus
type I and celiac disease, are more common and
recognizable in high school and collegiate populations.
Others are rare and more difficult to recognize and
diagnose. Wegener granulomatosis is one of these disor-
ders. Classified as an illness associated with antibody-
mediated injury, it most often affects the lungs, respiratory
tract, kidneys, sinus and nasal passages, blood vessels, and
eyes.2–4 Approximately 90% of patients who present with
symptoms have sinus or lung (or both) involvement. Most
patients with this disorder also develop renal failure.3,5,6
Although rare, eye symptoms can include pain, pressure,
vision loss, and protrusion of the globe from the orbit5;
these symptoms indicate the presence of Wegener granu-
lomatosis.
Typically, Wegener granulomatosis affects people in
their 40s and 50s, although approximately 15% of cases are
seen in people younger than 20 years of age. The mean age
of diagnosis is 55 years.5,6 Wegener granulomatosis can
occur in both sexes but is most commonly seen in males.3
In many patients, 2 types of antibodies have been
identified. This means that Wegener granulomatosis could
be genetically linked, but studies3 have been inconclusive.
What makes Wegener granulomatosis a devastating
disorder is that the signs and symptoms may not be true
indicators of disease severity; progression to the deadly
form may occur over years2 and may include pulmonary
hemorrhages and fibrosis of the lungs or kidneys (or both),
which can cause blockages and leave the organs function-
ally insufficient.3,6 Treatments are aggressive, often requir-
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ing the use of corticosteroids, such as prednisone, and
chemotherapy drugs (cyclophosphamides) to fight the
various antibodies attacking the patient’s cells.1–3,5 The
first stage of treatment attempts to control the disease and
put it into a stage of remission. The second stage focuses on
controlling the remission, which calls for progressing from
one type of medication to another in various dosages to
prevent complications and relapse.2,4,6 If left untreated, the
disease may be fatal.7 However, treatment is generally
successful, and the prognosis is positive, with more than
75% of patients going into complete remission. Moreover,
survival rates have increased to greater than 20 years after
diagnosis for younger patients, although in older patients,
the average survival rate is lower.2,4,5 Survival rates in
elderly people are generally only a few years.2,4,5
Another autoimmune disorder, immunoglobulin A (IgA)
nephropathy, is the result of abnormal accumulation of the
IgA protein in the kidneys, causing renal blockages and
damage and ultimately leading to renal insufficiency. Also
known as Berger disease, IgA nephropathy is the most
common form of glomerulonephritis in the world.3,8,9
Glomerulonephritis is the inflammation of tissues (glomer-
uli) that filter blood in the kidney.8 This disease is more
common in males, with higher incidence rates in Japan,
Australia, and southern Europe and lower rates through-
out North America and the United Kingdom.3,8 Because of
strong familial patterns, current research10 points to
environmental or genetic factors as causes of the mutations
that result in IgA nephropathy. A link also seems to exist
between IgA nephropathy and hypertension in families,
making the latter a potential predisposing factor.11
As is the case with Wegener granulomatosis, the diagnosis
of IgA nephropathy is difficult, because it is often accom-
panied by few signs and symptoms. Renal failure from IgA
often occurs in combination with vascular deterioration,
which may result from Wegener granulomatosis.3 The main
sign is hematuria, but sometimes the amount of hematuria
may be so negligible that it only can be detected by advanced
testing procedures. Thus, early detection and identification
can be a challenge. Another discrete sign is excess protein in
the urine, which indicates that the kidneys are not properly
filtering waste products.5 As the kidneys begin to fail, the
patient may develop referred pain in the back below the ribs,
an increased need to urinate, fatigue, nausea, swelling of the
hands and feet, and increased blood pressure.3,8,12 A total of
20% to 40% of those with a definitive diagnosis develop end-
stage renal failure.6,13 If the disease is suspected, the patient
needs to undergo a kidney biopsy to search for the presence
of IgA deposits.12
Treatment involves immunosuppressant medications,
which help the patient feel better but do not preserve renal
function.3 Other medications, such as diuretics, are used to
regulate blood pressure and to try to protect the kidneys by
using hormones and steroids to reduce the immune
response. Medications may be added or changed post-
diagnosis.1,9 Some researchers13–15 have examined the
efficacy of fish oils and increased vitamin E intake to help
control symptoms of IgA nephropathy, especially in the
early stages or with unconfirmed test results. Cardiovas-
cular complications are more common in patients who are
smokers or who have hypertension. Wegener granulo-
matosis and IgA neuropathy should be treated indepen-
dently.15
CASE REPORT
A 19-year-old female collegiate basketball player pre-
sented to the athletic trainer with complaints of ocular
pain, redness, and irritation in mid-December of her
freshman year (Table). Initially, she treated her symptoms
with an over-the-counter anti-inflammatory medication
(ibuprofen) in an attempt to resolve her symptoms. A
month after the self-treatment, her eyes remained blood-
shot and the pain persisted. The patient was referred by her
athletic trainer to the emergency department, where she
was diagnosed with a sinus infection and referred to an
ophthalmologist. After seeing various doctors without
diagnosis or resolution of symptoms, she was placed on
Tobradex (Alcon Inc, Hunenberg, Switzerland), a cortico-
steroid in ocular form, by her ophthalmologist. Her eyes
began to improve, and she was able to complete the
basketball season without incidence. However, within
weeks of completing the season, she reported to the
athletic training department with a return of her symptoms
at a more intense and persistent level. At this point, she was
referred to another physician, who referred her to a cornea
specialist, who diagnosed her with scleritis. After consult-
ing 2 other eye specialists, she was placed on prednisone
(dosage unknown) and found immediate relief of all signs
and symptoms.1
After successful treatment with prednisone, the patient’s
dosage was decreased. Shortly thereafter, symptoms of
intense ocular pain and a bloodshot appearance of the
sclera returned; she also complained of headaches. Her
physician ordered blood tests, which were positive for anti-
neutrophil cytoplasmic antibodies, commonly associated
with various immunologic disorders.1,5 The physicians
suspected Wegener granulomatosis and referred her to a
rheumatologist. He concurred with the diagnosis and
prescribed Imuran (dosage unknown; Prometheus Labo-
ratories Inc, San Diego, CA), a chemotherapeutic drug that
is used as an immunosuppressent.1,4 The patient remained
on this medication regimen for approximately 9 months.
Symptoms attenuated, and the patient continued regular
follow-up visits with her cornea specialist and rheumatol-
ogist. Routine tests in September 2006 showed that more
than 3 g of protein was detected in her urine. Again,
Wegener granulomatosis was suspected, and she was
referred to a nephrologist, who ordered a kidney biopsy.
The biopsy was positive for IgA nephropathy. She was
placed on Lisinopril (dosage unknown; Lupin Pharmaceu-
ticals, Inc, Baltimore, MD), which is commonly prescribed
to treat hypertension and congestive heart failure. Because
of the side effects of the medications, wound healing at the
biopsy site was prolonged, and she was medically restricted
from participation in basketball for more than 2 weeks.
Once medically cleared, she was able to complete the
basketball season without further complication. With close
communication among her physicians and athletic trainer,
she successfully began decreasing her prednisone dosage.
She continued follow-up visits with the cornea specialist
and nephrologist, who took over her testing and medical
care. She discontinued care with her rheumatologist for
personal reasons.
In June 2007, the patient developed conjunctivitis and
had a relapse of symptoms but was able to continue
activity. Upon returning to school in September 2007, she
consulted the cornea specialist and was informed that her
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vision had decreased markedly since the previous spring.
She was then referred to a retinal specialist, who found that
both the retina and optic nerve were swollen and increased
her prednisone to 20 mg from the progressively reduced
dosage. Her dosage of prednisone was increased signifi-
cantly, and she was referred to a rheumatologist who
specialized in Wegener disease. The rheumatologist deter-
mined that she needed a lower dosage of prednisone and
discontinued the Imuran because he believed it was
ineffective at this stage. He prescribed methotrexate
(dosage unknown), which is similar in function to Imuran
and prednisone but helps to protect kidney function.1,4
After starting methotrexate, she again developed inflam-
mation in her right eye, which required an intraocular
injection of prednisone in December 2007.
The following month, while taking 3 drugs (Tobradex,
Lisinopril, and methotrexate), the athlete developed a
staphylococcal infection (unrelated to her conditions) that
required surgical intervention. Again, as with the kidney
biopsy, the immunosuppressant drugs hindered healing,
and she was unable to return to play for approximately
3 weeks. Upon return to play after the injection and
surgery, she dealt with extreme fatigue and developed foot
pain in the fifth metatarsal. The athletic trainer referred her
Table. Athlete’s Medical Timeline
Date Age, y Signs and Symptoms Treatment and Medications Comments
Mid-December 2005 19 N Ocular pain
N Acute iritis
N Ibuprofen
January 2006 19 N Persistent eye pain
N Ocular pressure
N Bloodshot eyes
N Emergency room visit
N Diagnosed with sinus infection




March–April 2006 19 N Increasing eye pain and
sensitivity
N Referred to cornea specialist
April 2006 19 N Intense eye pain N Diagnosed with scleritis
N Prescribed prednisone
Symptoms nearly resolved
August 2006 20 N Persistent eye pain
N Headaches
N Acute iritis reappeared after
prednisone dose decreased
N Physicians began to suspect
Wegener granulomatosis
N Sent for blood panel
N Referred to rheumatologist
September 2006 20 N Eye pain
N Iritis
N Began Imuranb
N Blood panel showed increase
in ANCA levels
N Referred to nephrologist
N Obtained kidney biopsy
N Prescribed Lisinoprilc




IgA nephropathy suspected and
confirmed
June 2007 21 N Contracted conjunctivitis






Lisinopril added to help address
IgA nephropathy
September 2007 21 N Deteriorating vision N Consulted cornea/retina
specialist
N Prednisone increased
N Methotrexate replaced Imuran
Methotrexate added to protect
kidney function
October 2007 21 N Developed unrelated
staphylococcal infection
N Continued on methotrexate Lost 3 wk of competition
because of slow healing rate
December 2007 21 N Eye issues resurfaced N Prednisone injected into right eye
Late-December
2007
21 N Developed foot pain (fifth
metatarsal)
N Referred to orthopaedist for foot
pain
N Radiographs, bone density tests
conducted
N Bone scan indicated stress
reaction
N Prescribed orthotics, supportive
modalities, rehabilitation
January–April 2008 21 N None N Continues to do well





Abbreviations: ANCA, anti-neutrophil cytoplasmic antibody; IgA, immunoglobulin A.
a Alcon, Inc, Hunenberg, Switzerland.
b Prometheus Laboratories, Inc, San Diego, CA.
c Lupin Pharmaceuticals, Inc, Baltimore, MD.
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to the team orthopaedic physician because of concern
that taking such high doses of prednisone while partici-
pating in basketball could lead to bone deterioration. The
orthopaedic physician ordered radiographs and a bone
scan and prescribed orthotics to help reduce stress on
the foot. The radiographs were negative; the bone
scan showed an uptake in contrast, indicating a stress
reaction. However, the physician did not recommend
discontinuing participation in basketball. The patient’s
treatment plan, which was coordinated by her athletic
trainer, included ice-cup massage and orthotic therapy for
the rest of the season to reduce symptoms. Arch taping was
used to relieve pressure on the foot until the orthotics were
delivered.
At the time of this case report, the patient’s treatment
has remained consistent and successful. The coordination
of care by the athletic trainer and the close communication
among the various physicians and the athletic trainer have
kept all parties well informed and have maintained
effective lines of communication. Her physicians continue
to work to reduce medication levels and to maintain
normal levels of protein in her urine as well as normal
kidney function. She resumed care with a rheumatologist
every 6 weeks and was able to consistently reduce her
prednisone dosage. She continues follow-up visits with her
ophthalmologist every 2 months and with her nephrologist
every 4 months. The eye pain, fatigue, and general
symptoms have, for the most part, resolved. Minor relapses
of all of her aforementioned physical ailments, such as eye
pain, fatigue, and others, have been controlled with
medication. She has been able to fully participate in all
training activities.
CONCLUSIONS
Although Wegener granulomatosis and IgA nephropa-
thy have been independently documented in collegiate
athletes, we are unaware of any documented cases of the
conditions occurring simultaneously in otherwise healthy
elite National Collegiate Athletic Association Division I
collegiate athletes. Although they share the similar
characteristics of autoimmune disorders affecting the
kidneys, with the potential for renal failure, Wegener
granulomatosis and IgA nephropathy are not commonly
seen together. This athlete originally presented with signs
and symptoms that could be identified as a sinus infection
but instead resulted in a life-altering diagnosis of 2
autoimmune disorders, which, if not recognized and
managed early, could have required a kidney transplant
or led to death.1,3,12 With its trademark vague signs and
symptoms consistent with other medical conditions, as well
as signs and symptoms that do not appear clinically for
years, Wegener granulomatosis poses a particular challenge
for the athletic trainer and the sports medicine team.2,5 As
previously mentioned, the elderly can be particularly
adversely affected because they may not be able to tolerate
the dosages of medications used to treat this disorder. Age
may have been a relative advantage for this athlete, as is
evident based on her success thus far in her sport
performance. Although the cause of Wegener granuloma-
tosis remains uncertain, both genetic mutations and
environmental factors, such as exposures to heavy metals
(eg, mercury, lead), silica, and aromatic hydrocarbons,
possibly through contaminated water sources, may con-
tribute to the development of this disorder.5,11
Autoimmune disorders, such as Wegener granulomato-
sis, can present with a variety of common signs and
symptoms. Athletic trainers may encounter a host of
unusual signs and symptoms in their athletes; however, in
cases such as this, further investigation into the chief
complaint(s) can go a long way to restoring or managing
an athlete’s health. In younger patients with Wegener
granulomatosis, the prognosis is usually positive, yet
complications such as vision loss and kidney dysfunction
can arise unexpectedly. Thus, regular monitoring is very
important. Our patient was a well-conditioned athlete, so
exercise may have moderated her recovery, although this
factor has not been examined in younger, physically active
athletes.1–4
Athletic trainers are often the first professionals to assess
these types of conditions, however common or rare. Being
aware of the diverse presentation of various autoimmune
diseases and disorders is an essential skill for any athletic
trainer and will help facilitate optimal care for patients.
Even though the combined occurrence of Wegener
granulomatosis and IgA nephropathy is relatively uncom-
mon in younger athletic populations, this case documents
the possibility of encountering less well-known autoim-
mune issues in athletes. Athletic trainers have the
professional responsibility to stay abreast of all types of
issues that may afflict their athletes and patients. Lastly,
excellent communication among and utilization of the
sports medicine team helped this athlete manage her
potentially life-threatening situation while at the same time
allowing her to remain active in her sport. Challenging our
paradigm of skills and training with new and unique cases
will allow for better clinical diagnosis, management, and
follow-up care for those we serve.
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